BH
BHC.US Bausch Health Companies Inc
- Market cap
- USD 3.13B
- P/E
- -
- P/B
- 18.78x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BHC.US undervalued?
Graham numberThe Graham number of Bausch Health Companies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bausch Health Companies Inc fundamental analysis
No fundamental analysis for Bausch Health Companies Inc yet.
Bausch Health Companies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devic…
Full company profileBausch Health Companies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bausch Health Companies Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.67B | 8.72B | 8.38B | 8.60B | 8.03B | 8.43B | 8.12B | 8.76B | 9.63B | 10.3B | 11.1B |
| Gross Profit | 7.10B | 6.18B | 6.03B | 6.25B | 5.78B | 6.04B | 5.76B | 6.20B | 6.84B | 7.25B | 8.10B |
| Operating Income | -566M | 102M | -2.38B | -203M | 676M | 450M | 454M | 963M | 1.55B | 2.19B | 3.04B |
| EBITDA | 4.07B | 3.41B | 3.32B | 3.42B | 3.14B | 3.26B | 2.88B | 2.89B | 3.13B | 3.18B | 2.20B |
| Net Income | -2.41B | 2.40B | -4.15B | -1.78B | -559M | -948M | -225M | -592M | -46.0M | 157M | -972M |
| EPS | -6.94 | 6.83 | -12 | -5.06 | -1.57 | -2.64 | -0.62 | -1.62 | -0.13 | 0.42 | -2.55 |
| Balance Sheet | |||||||||||
| Total Assets | 43.5B | 37.5B | 27.4B | 33.9B | 31.2B | 29.2B | 25.7B | 27.4B | 26.5B | 26.3B | 25.5B |
| Total Liabilities | 40.3B | 31.6B | 29.7B | 32.7B | 30.6B | 29.2B | 25.4B | 27.4B | 26.8B | 25.9B | 25.8B |
| Shareholders' Equity | 3.15B | 5.85B | 2.73B | 1.06B | 605M | -34.0M | -692M | -1.02B | -1.28B | -553M | -1.33B |
| Cash & Short-term Investments | 542M | 720M | 721M | 3.24B | 605M | 582M | 564M | 947M | 1.18B | 1.32B | 2.49B |
| Total Debt | 29.8B | 25.4B | 24.3B | 25.9B | 24.0B | 22.7B | 20.8B | 22.4B | 21.8B | 21.2B | 20.7B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.09B | 2.29B | 1.50B | 1.50B | 1.11B | 1.43B | -728M | 1.03B | 1.60B | 1.40B | 2.29B |
| Capital Expenditure | 291M | 336M | 235M | 278M | 309M | 283M | 268M | 272M | 337M | 397M | 387M |
| Free Cash Flow | 1.80B | 1.95B | 1.27B | 1.22B | 802M | 1.14B | -996M | 760M | 1.26B | 1.00B | 1.90B |
| Ratios | |||||||||||
| ROE | -76.4% | 41.1% | -151.8% | -167.7% | -92.4% | - | - | - | - | - | - |
| ROA | -5.5% | 6.4% | -15.1% | -5.3% | -1.8% | -3.2% | -0.9% | -2.2% | -0.2% | 0.6% | -3.8% |
| Net Profit Margin | -24.9% | 27.6% | -49.5% | -20.7% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% | -8.8% |
| Debt to Equity | 9.47x | 4.35x | 8.89x | 24.36x | 39.63x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bausch Health Companies Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Nov 10, 2010
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 31.0M | 0.09 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 18.0M | 0.05 | 0.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Oct 16, 2000.
Who owns Bausch Health Companies Inc
- Insiders 11.12%
- Institutions 65.00%
- Public & others 23.89%
- Shares outstanding 374M
- Free float 261M
Top funds holding BHC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Total Intl Stock Index Inv | 3.76M | 1.01% | 0.00% | Sep 2026 |
| Fidelity Canadian Value ETF | 3.17M | 0.85% | +0.05% | Oct 2026 |
| Vanguard Developed Markets Index Admiral | 2.47M | 0.66% | 0.00% | Sep 2026 |
| iShares Core S&P/TSX Cap Composite ETF | 1.87M | 0.50% | +0.03% | Oct 2026 |
| RBC QUBE Canadian Equity F | 1.84M | 0.49% | 0.00% | Sep 2026 |
| Fidelity All-in-One Growth ETF F | 1.78M | 0.48% | +3.60% | Jun 2026 |
| Schwab Fundamental International Eq ETF | 1.43M | 0.38% | 0.00% | Oct 2026 |
| Fidelity All-in-One Balanced ETF F | 1.03M | 0.27% | +4.11% | Jun 2026 |
| BMO S&P/TSX Capped Composite ETF | 964K | 0.26% | +0.08% | Oct 2026 |
| RBC QUBE Low Vol Canadian Eqty Fund F | 954K | 0.26% | 0.00% | Sep 2026 |
| Vanguard FTSE All-Wld ex-US SmCp Idx Ins | 942K | 0.25% | -5.72% | Sep 2026 |
| Vanguard FTSE Canada All Cap ETF | 898K | 0.24% | +1.12% | Sep 2026 |
| DFA International Small Company I | 840K | 0.22% | +6.68% | Sep 2026 |
| Fidelity All-in-One Equity ETF Ser F | 816K | 0.22% | +4.93% | Jun 2026 |
| 1832 AM Quant Canadian Sm Cap Eq Pool KM | 649K | 0.17% | 0.00% | Sep 2026 |
| DFA International Core Equity 2 I | 595K | 0.16% | 0.00% | Sep 2026 |
| Schwab International Small-Cap Eq ETF™ | 530K | 0.14% | +0.53% | Oct 2026 |
| TD Emerald Canadian Equity Index | 488K | 0.13% | +0.33% | Jun 2026 |
| Desjardins RI Multifactor Cndn Eq ETF | 447K | 0.12% | 0.00% | Oct 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 411K | 0.11% | 0.00% | Oct 2026 |
Top institutions holding BHC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Paulson & Company Inc | 73.3M | 19.57% | 0.00% | Jun 2026 |
| Goldentree Asset Management LP | 34.7M | 9.26% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 10.8M | 2.89% | -4.67% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 8.00M | 2.14% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 7.47M | 1.99% | +0.83% | Jun 2026 |
| The Goldman Sachs Group Inc | 6.23M | 1.66% | +19.53% | Jun 2026 |
| MFN Partners Management, LP | 6.00M | 1.60% | 0.00% | Jun 2026 |
| SG Americas Securities, LLC | 5.54M | 1.48% | +37,278.60% | Jun 2026 |
| Acadian Asset Management LLC | 5.48M | 1.47% | +12.37% | Jun 2026 |
| Kohlberg Kravis Roberts & Co LP | 5.24M | 1.40% | 0.00% | Jun 2026 |
| Hudson Bay Capital Management LP | 5.00M | 1.34% | 0.00% | Jun 2026 |
| ING Groep NV | 5.00M | 1.34% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 4.80M | 1.28% | +13.59% | Jun 2026 |
| Gendell Jeffrey L | 4.04M | 1.08% | +35.94% | Jun 2026 |
| NORGES BANK | 3.43M | 0.92% | -6.83% | Jun 2026 |
| Macquarie Group Ltd | 3.25M | 0.87% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.03M | 0.81% | -6.42% | Sep 2026 |
| D. E. Shaw & Co LP | 2.69M | 0.72% | +332.64% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 2.25M | 0.60% | +1.34% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.24M | 0.60% | +65.58% | Jun 2026 |
Bausch Health Companies Inc company profile
- Company name
- Bausch Health Companies Inc
- Ticker
- BHC.US
- ISIN
- CA0717341071
- Exchange
- USA Stocks
- Listed since
- Mar 29, 1994
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,300
- Fiscal year end
- December
- Address
- 2150 St. Elzéar Blvd. West, Laval, QC, Canada, H7L 4A8
- Phone
- 514 744 6792
- Website
- bauschhealth.com
About Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc management
10- Mr. Thomas J. AppioCEO & Director · born 1962
- Mr. Jean-Jacques CharhonExecutive VP & CFO · born 1965
- Ms. Seana CarsonExecutive VP & General Counsel · born 1973
- Ms. Aimee J. LenarPresident of US Pharma · born 1976
- Mr. Mirza DautbegovicExecutive VP & COO
- Mr. Steven H. LeeSenior VP, Controller & Chief Accounting Officer · born 1971
- Mr. Garen SarafianVP & Head of Investor Relations
- Ms. Kathleen FitzpatrickExecutive VP and Chief HR & Communications Officer
- Mr. Cees HeimanSenior Vice President of Europe & Canada
- Ms. Jiny Kim M.B.A.Senior Vice President of Solta Medical · born 1977